“Don’t Worry About the NIH” From the Same Doctors Who Brought You “Don’t Worry About COVID.”

The Comforting Phrase That Should Make You Uncomfortable

“Don’t worry” is a wonderful sentence when it comes from a pilot after mild turbulence. It is less reassuring when it comes from people discussing a pandemic, a national research agency, or a budget mechanism complicated enough to make an accountant quietly close the spreadsheet and go for a walk.

The title of this debate emerged from criticism of physicians and commentators who minimized the danger of COVID-19 and later minimized threats to the NIH. One prominent example was cardiologist John Mandrola, who argued in early 2025 that medical science would be fine if NIH-supported work resembling weak observational studies disappeared. Critics noted that he had used similarly confident language during the pandemic, including predictions in 2020 that U.S. hospitals were prepared and that New York City-style crises were unlikely to recur. The study he cited while criticizing NIH spending was not itself funded by the agency, although its investigators disclosed NIH support for other work.

The issue is not whether every NIH-funded study is brilliant. Of course it is not. Science produces dead ends, underpowered studies, overhyped press releases, and occasional papers that seem to have been designed by three raccoons sharing a statistics textbook. The real question is whether isolated examples of mediocre research justify broad cuts to the system that supports high-quality research as well.

What the NIH Actually Does

The National Institutes of Health is the United States’ principal public funder of biomedical research. It supports work conducted on its own campuses and, more importantly for this controversy, distributes grants to universities, hospitals, medical schools, and research institutes across the country. Those grants support basic biology, cancer research, neuroscience, infectious disease studies, clinical trials, training programs, and the long, uncertain path from a laboratory observation to a treatment used in a clinic.

NIH funding is not a decorative bonus attached to American medicine. A major analysis published in the Proceedings of the National Academy of Sciences found that NIH-supported research was associated with every one of the 210 new drugs approved by the Food and Drug Administration from 2010 through 2016. More than 90% of that support involved basic research related to biological targets rather than direct development of the finished drug. That is precisely why basic science can look unglamorous right up until it becomes indispensable.

Why “Indirect Costs” Are Not Imaginary Costs

In February 2025, the Trump administration’s NIH announced that indirect-cost reimbursement on grants would be capped at 15%. The policy was presented as a way to redirect money away from overhead and toward experiments. The word overhead did a heroic amount of political work. It encouraged people to imagine mahogany conference tables, executive retreats, and perhaps a vice provost whose primary research interest is catered lunch.

Actual facilities and administrative costs include laboratory space, electricity, ventilation, hazardous-waste disposal, research security, financial oversight, cybersecurity, animal-care facilities, maintenance of shared instruments, and compliance systems for protecting human participants. A freezer holding irreplaceable samples does not care whether its electricity bill is categorized as scientifically glamorous. It simply stops working when the power stops.

Another source of confusion was the percentage itself. A negotiated indirect-cost rate of 50% does not usually mean half of the total grant vanishes into administration. The rate is generally applied to a restricted base that excludes items such as major equipment, patient-care costs, tuition, and portions of subawards. Reuters reported that the effective average had been roughly 27% to 28% of grant funding, while the administration said the cap could save about $4 billion.

The COVID Parallel: Confidence Arrived Before the Evidence

The comparison with COVID is not that a funding policy and a respiratory virus are identical. They plainly are not. The parallel is rhetorical: select a reassuring slice of reality, ignore the system-level risk, and describe concern as panic.

During 2020, statements that hospitals were ready or that major surges were unlikely proved badly timed. Federal investigators later surveyed hundreds of hospitals and found that many were operating in prolonged “survival mode,” struggling with staffing, supplies, routine care, and the resource-intensive treatment of COVID-19 patients. CDC researchers also linked high hospital strain to additional excess deaths, estimating that nationwide intensive-care occupancy at 75% could be followed by thousands of extra deaths.

COVID also did not remain a problem only for the oldest Americans. Age was a major risk factor, but national mortality analyses found that COVID-19 became a top-five cause of death for every age group 15 and older during portions of 2020 and 2021. In 2021 alone, the CDC recorded more than 460,000 deaths in which COVID-19 was an underlying or contributing cause.

None of this means every restriction was wise, every official statement was accurate, or every vaccine policy was perfectly calibrated. Serious criticism of pandemic policy is necessary. But serious criticism counts harms on both sides. It does not magnify rare adverse events while shrinking hospital collapse, death, disability, and delayed care into the footnotes.

How Minimization Works

1. Find the Weakest Study and Pretend It Represents the Whole Portfolio

A large research agency will inevitably fund projects of uneven quality. Pointing to one flimsy observational study and declaring the broader system wasteful is like finding a disappointing sandwich at an airport and demanding the abolition of aviation.

Better reform would examine replication, publication bias, administrative burden, grant-review quality, conflicts of interest, and whether funds are concentrated too heavily among established institutions. Those are legitimate policy questions. A blanket cap applied with little warning is not the same thing as carefully designed reform.

2. Turn Infrastructure Into a Punchline

The phrase “money should go to scientists, not overhead” sounds sensible until one notices that scientists require buildings, technicians, ethics boards, secure servers, clean rooms, biosafety systems, and working equipment. A laboratory without infrastructure is not a lean laboratory. It is an expensive room where nothing reliable can happen.

3. Treat Uncertainty as Proof That Nothing Bad Will Happen

Scientific uncertainty cuts both ways. If the consequences of a sudden funding change are unclear, that is an argument for staged implementation, transparent modeling, and monitoringnot for assuming that clinical trials and laboratories will somehow absorb the shock through positive thinking and departmental bake sales.

4. Forget the Previous Forecast

Public debate has a remarkably short warranty. A confident prediction fails, the speaker moves on, and anyone who remembers is accused of being divisive. Yet track records matter. Expertise is not merely a collection of credentials; it also includes calibration, willingness to correct errors, and honesty about uncertainty.

What Happened to the 15% NIH Cap?

The cap was challenged almost immediately by states, universities, medical schools, hospitals, and research organizations. A federal court blocked it, later issued a permanent injunction, and found that the policy conflicted with federal law and required procedures. In January 2026, the U.S. Court of Appeals for the First Circuit upheld the ruling. The Justice Department then allowed the April 6, 2026 deadline for requesting Supreme Court review to pass, leaving the permanent injunction in place. The proposed NIH cap therefore never took effect.

That legal defeat did not erase the broader disruption. NIH grant reviews slowed, awards were delayed, and thousands of active grants were terminated or suspended during 2025. A 2026 analysis reported 2,291 terminated active grants totaling approximately $2.45 billion, while the Association of American Medical Colleges documented a multibillion-dollar shortfall in awards during part of fiscal year 2025. Some grants were later reinstated through litigation, but experiments cannot always be restarted like a paused video. Staff leave, samples expire, animal colonies are lost, enrollment windows close, and trainees choose more stable careers.

Why Private Foundations Cannot Simply Replace the NIH

Supporters of the 15% cap sometimes compared NIH grants with awards from private foundations that reimburse lower indirect-cost rates. The comparison sounds persuasive until the funding models are examined.

Many private foundations expect universities to subsidize part of the research from endowments, hospital revenue, philanthropy, or other grants. Some fund a narrow range of projects, offer smaller awards, or support programs for shorter periods. They may also benefit from laboratories and compliance systems that federal grants helped build and maintain.

A wealthy university might absorb part of a sudden federal cut, although even large institutions would face difficult choices. A regional medical center, public university, historically Black institution, rural hospital, or independent research institute may have no enormous endowment waiting behind a curtain. A universal cap could therefore shift research toward the small group of institutions rich enough to subsidize it themselves.

That would be an odd result for a policy advertised as a strike against elite universities. The institutions most capable of surviving would be the elites. Smaller centers, local clinical-trial sites, and emerging research programs could be the first to retreat.

Reasonable NIH Reform Is Not Institutional Sabotage

The NIH should not be immune from scrutiny. Peer review can favor safe projects and established investigators. Administrative requirements can consume absurd amounts of time. Universities should explain negotiated rates clearly, disclose how reimbursements are used, and show that research infrastructure is managed efficiently. Congress and the public deserve measurable results.

But the correct response to a complicated system is not to pretend it is simple. A thoughtful reform plan would use audited cost data, distinguish wealthy institutions from smaller hospitals and regional universities, protect ongoing clinical trials, phase in changes, and evaluate effects on research output, patient safety, and the scientific workforce. It would invite public comment before implementation rather than after laboratories have begun calculating which freezers they can afford to keep cold.

Reforms could also reward institutions that share expensive equipment, simplify duplicative reporting, improve study reproducibility, publish negative findings, and reduce the time researchers spend navigating paperwork. These ideas may lack the dramatic charm of announcing one universal percentage on social media, but policy is usually better when it is slightly less exciting.

Most importantly, reform should be led by evidence rather than resentment. The purpose of NIH funding is not to reward universities for being virtuous. It is to produce knowledge that private markets often underfund because the payoff is uncertain, distant, or broadly shared. Basic research is a public good precisely because no single company can reliably capture all of its benefits.

Experiences Behind the NIH Funding Debate

The following scenarios are composites based on commonly reported experiences across U.S. research institutions. They are not presented as quotations from specific individuals.

The Early-Career Researcher

Imagine a postdoctoral scientist studying a rare pediatric cancer. Her salary comes from one grant, the sequencing core she uses is maintained through shared institutional funds, and the freezer holding tumor samples is connected to an emergency-power system. On paper, only her experiments are considered direct research costs. In practice, the project depends on dozens of invisible services.

When funding becomes uncertain, she does not merely postpone buying pipette tips. She begins applying for industry positions. Six months later, the grant may return, but the person trained to run the project is gone. Recruiting and training a replacement could take another year. The scientific question did not become less important. The career became less survivable.

The Clinical Trial Participant

A patient joins a clinical trial because standard treatment has stopped working. The study requires nurses, pharmacists, data managers, laboratory testing, secure records, adverse-event reporting, and an institutional review board. Much of that infrastructure is shared across dozens of trials.

When people hear “cut overhead,” they may picture a smaller administrative office. The patient experiences it as fewer appointment slots, slower enrollment, delayed test results, or a trial that never opens at the local hospital. For that patient, research infrastructure is not an abstract accounting category. It is the bridge between a promising treatment and an actual infusion chair.

The Laboratory Manager

A laboratory manager sees the budget from a less romantic angle. She knows the annual service contract for a microscope, the cost of replacing a compressor, and how quickly a biosafety cabinet becomes useless without certification. She knows which backup freezer contains the samples when another unit fails at 2 a.m.

She also knows that researchers routinely improvise to save money. They share reagents, repair aging equipment, and stretch supplies as far as quality standards allow. A sudden funding shock does not necessarily reveal a hidden pile of luxury spending. It often reveals how close the system was already operating to the edge.

The Hospital Clinician

A physician who worked through COVID remembers another kind of minimization. In the spring, someone said hospitals were ready. By winter, hallways were crowded, staff members were exhausted, transfers were difficult, and routine care was delayed.

That memory changes how the clinician hears promises that research institutions will be “fine.” The concern is not that every warning will come true. It is that confident reassurance can become a substitute for preparationand preparation is generally much cheaper before a system fails.

The University Administrator

An administrator receives plenty of criticism, some of it deserved. Yet the person responsible for research compliance must ensure that grants follow federal accounting rules, patients give informed consent, conflicts of interest are disclosed, laboratory animals receive proper care, and sensitive medical data remain secure.

Removing unnecessary forms is good reform. Removing the people who prevent fraud, unsafe experiments, and data breaches is not. The challenge is distinguishing bureaucracy that protects research from bureaucracy that merely protects bureaucracy. A universal percentage cannot make that distinction.

The Taxpayer

The taxpayer has every right to ask whether a grant is useful and whether a university’s negotiated rate is justified. But the taxpayer also deserves an honest invoice. Electricity, cybersecurity, research-subject protection, hazardous-waste handling, equipment maintenance, and financial audits are not optional merely because they do not fit neatly in a photograph of a scientist holding a test tube.

Transparency should expose real waste without rebranding necessary costs as waste for applause. Otherwise, taxpayers may celebrate a lower bill today and discover later that they also purchased fewer trials, fewer trained scientists, and fewer chances for the next medical breakthrough.

These experiences point to the same lesson: science is a network, not a stack of isolated experiments. Remove enough unglamorous supports and the glamorous discoveries do not become cheaper. They become less likely.

Conclusion: Worry Less About Slogans, More About Systems

The NIH debate was never just about one percentage. It was about how Americans evaluate risk, expertise, and public institutions after COVID. Skepticism is healthy. Memory is healthier. When a commentator who confidently minimized one system-wide danger confidently minimizes another, the proper response is not automatic rejectionbut it is certainly not automatic trust.

The 15% indirect-cost cap was stopped in court, yet the episode demonstrated how quickly research can be destabilized by policy designed for maximum rhetorical impact. NIH reform should continue, but it should proceed with transparent evidence, legal authority, gradual implementation, and protection for patients and ongoing studies.

So, should Americans worry about the NIH? They should worry enough to ask precise questions. Which costs are wasteful? Which are essential? What evidence supports the change? Who bears the risk if the forecast is wrong?

That is not panic. It is the habit of mind that science itself is supposed to teach.